CRLX101 Plus Bevacizumab in Advanced RCC

Summary

This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in combination with Bevacizumab in patients with advanced renal cell carcinoma. The purpose of this study is to determine the initial safety and effectiveness of this agent in combination with Bevacizumab. The investigators are also trying to determine the best dose level of CRLX101 to give in combination with bevacizumab. About 22 subjects will be enrolled in this study at the University of Pennsylvania.

Timeline

Start

2012-06

Primary completion

2017-07-01

Completion

2018-07-16

Drugs

Indications